Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors

被引:13
|
作者
Zhu, Fugui [1 ,2 ]
Meng, Xiangguo [3 ]
Liang, Huixin [1 ,2 ]
Sheng, Chunquan [2 ]
Dong, Guoqiang [2 ]
Liu, Dan [1 ]
Wu, Shanchao [2 ]
机构
[1] Shenyang Pharmaceut Univ, Key Lab Struct Based Drugs Design & Discovery, Minist Educ, Shenyang 110016, Liaoning, Peoples R China
[2] Second Mil Med Univ, Sch Pharm, Dept Med Chem, 325 Guohe Rd, Shanghai 200433, Peoples R China
[3] Shanghai Univ Med & Hlth Sci, Coll Pharm, 279 Zhouzhugong Rd, Shanghai 201318, Peoples R China
基金
中国国家自然科学基金;
关键词
Evodiamine; Topoisomerase; Histone deacetylase; Drug design; Structure-activity relationship; Antitumor activity; MULTIPLE LIGANDS; HIGHLY POTENT; DISCOVERY; CANCER; POLYPHARMACOLOGY; DERIVATIVES; CHALLENGES; TARGET;
D O I
10.1016/j.bioorg.2022.105702
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
On the basis of synergistic effect between topoisomerase (Top) and histone deacetylase (HDAC) inhibitors, a series of novel evodiamine-based Top/HDAC dual inhibitors were designed and synthesized. Systematic structure-activity relationship (SAR) studies led to the discovery of compounds 29b and 45b, which simultaneously inhibited Top and HDAC and exhibited potent antitumor activities against the HCT116 cell line. Compounds 29b and 45b efficiently induced apoptosis with G2 cell cycle arrest and significantly inhibited cellular HDACs in HCT116 cells with good in vitro metabolic stabilities. Collectively, this work provides valuable SAR information and lead compounds for evodiamine-based Top/HDAC dual inhibitors.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
    Huang, Yahui
    Chen, Shuqiang
    Wu, Shanchao
    Dong, Guoqiang
    Sheng, Chunquan
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (07) : 1294 - 1308
  • [2] The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors
    Shultz, Michael
    Fan, Jianmei
    Chen, Christine
    Cho, Young Shin
    Davis, Nicole
    Bickford, Sheri
    Buteau, Kristen
    Cao, Xueying
    Holmqvist, Mats
    Hsu, Meier
    Jiang, Lei
    Liu, Gang
    Lu, Qiang
    Patel, Chetan
    Suresh, Joghee Raju
    Selvaraj, Mannangatti
    Urban, Laszlo
    Wang, Ping
    Yan-Neale, Yan
    Whitehead, Lewis
    Zhang, Haiyan
    Zhou, Liping
    Atadja, Peter
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (16) : 4909 - 4912
  • [3] A structure-activity relationship survey of histone deacetylase (HDAC) inhibitors
    Bozorgi, Atefeh Hajiagha
    Bagheri, Mehdi
    Aslebagh, Roshanak
    Rajabi, Mansoureh Sadat
    CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2013, 125 : 132 - 138
  • [4] Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy
    Wu, Shanchao
    Huang, Yahui
    Wang, Ting
    Li, Keliang
    Lu, Junjie
    Huang, Min
    Dong, Guoqiang
    Sheng, Chunquan
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (06) : 4818 - 4831
  • [5] One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites
    Diedrich, Daniela
    Stenzel, Katharina
    Hesping, Eva
    Antonova-Koch, Yevgeniya
    Gebru, Tamirat
    Duffy, Sandra
    Fisher, Gillian
    Schoeler, Andrea
    Meister, Stephan
    Kurz, Thomas
    Avery, Vicky M.
    Winzeler, Elizabeth A.
    Held, Jana
    Andrews, Katherine T.
    Hansen, Finn K.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 801 - 813
  • [6] Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships
    Poli, Giulio
    Di Fabio, Romano
    Ferrante, Luca
    Summa, Vincenzo
    Botta, Maurizio
    CHEMMEDCHEM, 2017, 12 (23) : 1917 - 1926
  • [7] Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity
    Mackwitz, Marcel K. W.
    Hesping, Eva
    Antonova-Koch, Yevgeniya
    Diedrich, Daniela
    Woldearegai, Tamirat Gebru
    Skinner-Adams, Tina
    Clarke, Mary
    Schoeler, Andrea
    Limbach, Laura
    Kurz, Thomas
    Winzeler, Elizabeth A.
    Held, Jana
    Andrews, Katherine T.
    Hansen, Finn K.
    CHEMMEDCHEM, 2019, 14 (09) : 912 - 926
  • [8] Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors
    Pabba, Chittari
    Gregg, Brian T.
    Kitchen, Douglas B.
    Chen, Zhen Jia
    Judkins, Angela
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (01) : 324 - 328
  • [9] DESIGN, SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF PYRILAMINE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
    Hiranaka, Seiya
    Arata, Mayumi
    Nakata, Akiko
    Tanaka, Akiko
    Hashizume, Yoshinobu
    Kudo, Norio
    Ito, Akihiro
    Yoshida, Minoru
    Uesato, Shinichi
    Nagaoka, Yasuo
    Sumiyoshi, Takaaki
    HETEROCYCLES, 2020, 101 (02) : 726 - 737
  • [10] Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase
    Marson, Charles M.
    Mahadevan, Thevaki
    Dines, Jon
    Sengmany, Stphane
    Morrell, James M.
    Alao, John P.
    Joel, Simon P.
    Vigushin, David M.
    Coombes, R. Charles
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (01) : 136 - 141